Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for KB801 in Neurotrophic Keratopathy. The expected timing is based on the latest available company guidance and may change.
EMERALD-1 Trial. 7/9/25- First patient dosed in Phase 1/2 trial. 11/03/25:- EMERALD-1 enrollment ongoing; FDA grants platform technology designation to KB801 HSV-1 vector. 02/17/26:- EMERALD-1 home-use protocol updated; enrollment ongoing; expect study data in 2026. 05/04/26:- EMERALD-1 registrational trial enrolling; expect full enrollment and KB801 NK data before year-end 2026. 08/03/26:- EMERALD-1 enrollment continues; completion expected before year-end.
Verification
Confirm timing and program details against the company announcement or filing.